Royalty Pharma
RPRX
RPRX
335 hedge funds and large institutions have $11.8B invested in Royalty Pharma in 2022 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 136 increasing their positions, 100 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
335
Holders Change
+17
Holders Change %
+5.35%
% of All Funds
5.4%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.15%
New
61
Increased
136
Reduced
100
Closed
36
Calls
$44.5M
Puts
$5.65M
Net Calls
+$38.9M
Net Calls Change
-$23.9M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$1.74B |
| 2 |
BlackRock
New York
|
$767M |
| 3 |
SVCF
Silicon Valley Community Foundation
Mountain View,
California
|
$40.8M |
| 4 |
Millennium Management
New York
|
$38.9M |
| 5 |
Renaissance Technologies
New York
|
$34.3M |
